Table 3.
Baseline characteristics between ER-PR+HER2+ and ER-PR-HER2+ subtypes before and after PSM
| Characteristics | Unmatched Cohort | 1:2 propensity score matched (PSM) Cohort | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
|
|
|
|||||||||
| ER-PR+HER2+ | ER-PR-HER2+ | Unadjusted | ER-PR+HER2+ | ER-PR-HER2+ | PSM-adjusted | |||||
|
|
|
|
|
|
|
|||||
| N=1050 | % | N=15728 | % | P value | N=1045 | % | N=2082 | % | P value | |
| Age at diagnosis | 0.287 | 0.646 | ||||||||
| <40 | 115 | 10.95% | 1415 | 9.00% | 112 | 10.72% | 191 | 9.17% | ||
| 40-49 | 212 | 20.19% | 3051 | 19.40% | 212 | 20.29% | 433 | 20.80% | ||
| 50-59 | 313 | 29.81% | 4915 | 31.25% | 311 | 29.76% | 666 | 31.99% | ||
| 60-69 | 227 | 21.62% | 3648 | 23.19% | 227 | 21.72% | 446 | 21.42% | ||
| 70-79 | 123 | 11.71% | 1811 | 11.51% | 123 | 11.77% | 237 | 11.38% | ||
| 80+ | 60 | 5.71% | 888 | 5.65% | 60 | 5.74% | 109 | 5.24% | ||
| Race | 0.989 | 0.661 | ||||||||
| White | 751 | 71.52% | 11203 | 71.23% | 748 | 71.58% | 1516 | 72.81% | ||
| Black | 118 | 11.24% | 1819 | 11.57% | 117 | 11.20% | 243 | 11.67% | ||
| Other | 169 | 16.10% | 2520 | 16.02% | 168 | 16.08% | 303 | 14.55% | ||
| Unknown | 12 | 1.14% | 186 | 1.18% | 12 | 1.15% | 20 | 0.96% | ||
| Histological type | 0.786 | 0.092 | ||||||||
| IDC | 945 | 90.00% | 14159 | 90.02% | 940 | 89.95% | 1912 | 91.83% | ||
| Non-IDC | 108 | 10.29% | 1569 | 9.98% | 105 | 10.05% | 170 | 8.17% | ||
| Marital | 0.943 | 0.828 | ||||||||
| Married | 601 | 57.24% | 8944 | 56.87% | 599 | 57.32% | 1201 | 57.68% | ||
| Unmarried | 392 | 37.33% | 5950 | 37.83% | 390 | 37.32% | 780 | 37.46% | ||
| Unknown | 57 | 5.43% | 834 | 5.30% | 56 | 5.36% | 101 | 4.85% | ||
| T stage | 0.009 | |||||||||
| T1 | 402 | 38.29% | 6769 | 43.04% | 402 | 38.47% | 815 | 39.15% | 0.893 | |
| T2 | 422 | 40.19% | 5843 | 37.15% | 422 | 40.38% | 843 | 40.49% | ||
| T3 | 108 | 10.29% | 1527 | 9.71% | 107 | 10.24% | 216 | 10.37% | ||
| T4 | 68 | 6.48% | 1057 | 6.72% | 67 | 6.41% | 130 | 6.24% | ||
| Tx | 50 | 4.76% | 532 | 3.38% | 47 | 4.50% | 78 | 3.75% | ||
| N stage | 0.096 | 0.094 | ||||||||
| N0 | 573 | 54.57% | 9042 | 57.49% | 570 | 54.55% | 1186 | 56.96% | ||
| N1 | 359 | 34.19% | 4780 | 30.39% | 357 | 34.16% | 687 | 33.00% | ||
| N2 | 57 | 5.43% | 952 | 6.05% | 57 | 5.45% | 123 | 5.91% | ||
| N3 | 45 | 4.29% | 757 | 4.81% | 45 | 4.31% | 72 | 3.46% | ||
| Nx | 16 | 1.52% | 197 | 1.25% | 16 | 1.53% | 14 | 0.67% | ||
| Grade | 0.631 | 0.250 | ||||||||
| Well | 12 | 1.14% | 226 | 1.44% | 11 | 1.05% | 20 | 0.96% | ||
| Moderately | 252 | 24.00% | 3554 | 22.60% | 249 | 23.83% | 444 | 21.33% | ||
| Poorly | 716 | 68.19% | 10841 | 68.93% | 715 | 68.42% | 1497 | 71.90% | ||
| Unknown | 70 | 6.67% | 1107 | 7.04% | 70 | 6.70% | 121 | 5.81% | ||
| median household income (inflation adjusted) | <0.001 | 0.696 | ||||||||
| <50,000 $ | 164 | 15.62% | 1580 | 10.05% | 159 | 15.22% | 311 | 14.94% | ||
| 50,000-59,999 $ | 171 | 16.29% | 2424 | 15.41% | 171 | 16.36% | 346 | 16.62% | ||
| 60,000-69,999 $ | 322 | 30.67% | 5443 | 34.61% | 322 | 30.81% | 680 | 32.66% | ||
| 70,000 $+ | 393 | 37.43% | 6281 | 39.94% | 393 | 37.61% | 745 | 35.78% | ||
| Radiotherapy | 0.877 | 0.626 | ||||||||
| No/unknown | 561 | 53.43% | 8450 | 53.73% | 560 | 53.59% | 1095 | 52.59% | ||
| Yes | 489 | 46.57% | 7278 | 46.27% | 485 | 46.41% | 987 | 47.41% | ||
| Chemotherapy | 0.525 | 0.081 | ||||||||
| No/unknown | 225 | 21.43% | 3511 | 22.32% | 225 | 21.53% | 392 | 18.83% | ||
| Yes | 825 | 78.57% | 12217 | 77.68% | 820 | 78.47% | 1690 | 81.17% | ||
| Surgery | 0.106 | 0.119 | ||||||||
| No | 94 | 8.95% | 1247 | 7.93% | 94 | 9.00% | 154 | 7.40% | ||
| Yes | 949 | 90.38% | 14428 | 91.73% | 944 | 90.33% | 1921 | 92.27% | ||
| Unknown | 7 | 0.67% | 53 | 0.34% | 7 | 0.67% | 7 | 0.34% | ||
ER+/-: estrogen receptor positive/negative; PR+/-: progesterone receptor positive/negative; HER2+/-: human epidermal growth factor receptor 2 positive/negative; PSM: propensity score matching.